Key facts
- Rapalogix Health’s last known valuation is $30.1M (Jun 2025).
- It has raised $9.1M across 1 recorded rounds; the latest was Early Stage VC ($9.1M) in Dec 2023.
- Notable investors include Quiet Capital, The Ax Incubator.
- Rapalogix Health has filed 2 Form Ds with the SEC since 2024, most recently Jun 2025 ($9.1M sold to 24 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Rapalogix Health
Funding rounds
1 roundsAbout Rapalogix Health
Developer of a biotechnology research platform designed to enhance skin health at the molecular level. The company offers tools that harness advances in regenerative medicine and longevity science to restore cellular balance, target skin diseases, and extend skin longevity, enabling individuals with skin issues to access approaches beyond traditional treatments and skincare.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 9
- Website
- rapalogix.com/
- Ownership
- Privately Held (backing)
Rapalogix Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rapalogix Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rapalogix Health in its N-PORT filings yet. We sweep new filings monthly.